Enter at least 3 characters

HOME > Press releases
 

PRESS RELEASES

Great Place To Work® and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
18 November 2024
Filsuvez® (birch bark extract gel) Now Available For Prescribing in Scotland for Epidermolysis Bullosa through SMC Ultra-Orphan Pathway Following Final Approval of the Data Collection Plan by Scottish Government
04 November 2024
Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of Pegunigalsidase Alfa▼ in Fabry Disease
29 October 2024
Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
28 October 2024
Clinically-validated computer-guided software to launch in up to 150 GP practices across Greater Manchester to support better adult asthma and COPD care
14 October 2024
Initial data from Hull collaboration project makes the case for nation-wide COPD diagnostic screening
09 September 2024
Chiesi Global Rare Diseases launches new research grant initiative to support research excellence in lysosomal storage disorders
05 September 2024
Two rare disease therapies approved in Scotland to be made available for people living with Fabry disease and epidermolysis bullosa
09 July 2024
Manchester-based biopharmaceutical company Chiesi comes out in force to boost local green spaces
04 July 2024
Study analysis supports reformulation of Chiesi’s triple therapy inhaler with low global warming potential propellant
12 June 2024
Chiesi Group forges alliance with Karolinska Institutet to tackle urgent health challenges
14 May 2024
Chiesi Group's 2023 revenue surpasses €3 billion mark, reflecting 10% growth year-on-year (+12% @CER), underlining commitment to innovative, sustainable practices
23 April 2024
Chiesi’s carbon minimal inhalers reach innovation milestone as phase III trials now underway
04 April 2024
Chiesi named one of the UK’s Best Workplaces™ 2024
28 March 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
07 March 2024
Chiesi announces carbon neutral respiratory portfolio
14 Feburary 2024
Chiesi recognised as a Top Employer in United Kingdom for 13th consecutive year
18 January 2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialise OHB-607, a potentially transformative neonatal therapy
10 January 2024
Chiesi named as a Great Place to Work-Certified™ Company
23 November 2023
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
20 November 2023
NICE recommends Lamzede®▼ (velmanase alfa) as first ever enzyme replacement therapy for initiation in children with alpha-mannosidosis in England and Wales in final evaluation document
09 November 2023
Chiesi Limited announces new senior level changes to leadership team
30 October 2023
Chiesi global rare diseases releases report on the burden of care for rare diseases and its economic impact on European citizens
30 October 2023
NICE highly specialised technologies guidance released for Filsuvez® gel (birch bark extract) in the treatment of epidermolysis bullosa
28 September 2023
Climate change threatens respiratory patients' quality of life stretching beyond physical health, new Economist report warns
07 September 2023
NICE recommends Elfabrio®▼(pegunigalsidase alfa) for adults with fabry disease in final draft guidance
01 September 2023
MHRA grants marketing authorisation for Elfabrio®▼(pegunigalsidase alfa) for the treatment of adult patients with fabry disease in Great Britain
16 August 2023
Chiesi Group mid-year financial results demonstrate strong growth 2023
04 August 2023
Chiesi recognised amongst UK’s Best Workplaces for Women for fourth consecutive year
20 July 2023
Chiesi global rare diseases announces FDA approval of Lamzede® (velmanase alfa-tycv)
16 March 2023
Chiesi Group calls for #ActionOverWords in the fight against climate change
10 May 2021
© 2024 Chiesi Limited
333 Styal Road Manchester M22 5LG
Registered in England and Wales No. 2140985. VAT Registration No. GB686750782
CHIESI ON THE WEB
FOLLOW US ON:
Details of Chiesi’s clinical trials can be found at www.clinicaltrials.gov
-